cancer cell News
-
Showcase
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest that onapristone adds to inhibition ...
-
FRONTBIO Inc Published a New Anticancer Drug Thesis Through Scientific Reports
FRONTBIO, a new drug development bio company, announced on the 12th that it will develop a new mechanism of anticancer drugs that can selectively amplify oxygen free radicals only in cancer cells by using differences in energy metabolism between normal cells and cancer cells. The first role of the compound drug is to selectively generate oxygen free radicals only in cancer cells to distinguish ...
By Frontbio
-
FRONTBIO Inc Published a Paper to Identify New Anticancer Mechanism CASRA
Through 'Scientific Reports,' a sister journal of the international academic journal Nature, FRONTBIO, a new drug development bio company, uses the difference in energy metabolism between n radicals in cancer cells. On the 12th, it was announced that a thesis related to an anticancer drug with a novel mechanism had been published. The new anticancer agent is a combination drug in which the first ...
By Frontbio
-
CD BioGlyco Announced Service for Analysis of Glycolytic Enzymes in Cancer Cells
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal ...
By CD BioGlyco.
-
Frédéric Leblond in the running for discovery of the year
The cancer cell detection probe developed by Louperivois Frédéric Leblond and Kevin Petrecca, of Polytechnique Montreal and the Montreal Neurological Institute and Hospital, could well be the discovery of the year in Quebec. Quebec Science magazine invites the public to vote for the discovery of the year 2017. The jury of experts brought together by the magazine selected 10 ...
-
Cancer Cell Therapy Products
Stem cell transplants have been widely used as a treatment for cancer since the 1960s. In 2010, the FDA approved Provenge, a product designed to treat late-stage prostate cancer. Cell therapy products designed for treating cancer are expected to be a growth segment for the industry over the next five years. According to the Alliance for Regenerative Medicine’s 2013 annual ...
-
FRONTBIO Inc Launches Preclinical Trials for its New Anticancer Drug
FRONTBIO a bio company that develops new pharmaceuticals announced on the 20th that it has developed a new anticancer drug that only kills cancer cells and will begin preclinical trials FRONTBIO confirmed the anticancer drug candidate FB320A3 signed a contract with the preclinical CRO Contract Research Organization and began the preclinical trials The phase 1 clinical trial will begin in 2022In ...
By Frontbio
-
Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive ...
-
Straight Outta Wisconsin, LynxBio Wins EvoNexus Best Demo Vote
A startup team from the University of Wisconsin that moved to San Diego in January to advance their technology for optimizing treatment regimens for cancer patients won the audience vote for best pitch at the EvoNexus Spring Demo Day last week. Lynx Biosciences founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer cells to determine ...
-
FRONTBIO Inc Presented at Pharmaceutical Science 2021 anti cancer mechanism
FRONTBIO Inc. Presented at Pharmaceutical Science 2021 Disclosure of ‘Cancer cell-specific active oxygen amplification mechanism complex anticancer drug’ Mechanism, etc. FRONTBIO, a new drug development bio company, announced on October 15th that CEO Lee Jae-Yong had been invited as a speaker to the 5th International Pharmaceutical and Advanced Drug Delivery System 2021 of AAC for ...
By Frontbio
-
Roswell Park introduces “Tactiva Therapeutics” as new Biotech Spinoff Company
BUFFALO, N.Y.(WKBW) – Lieutenant Governor Kathy Hochul, Dr. Candace Johnson and a special team of doctors at Roswell Park announced the launch of a new innovative Immunotherapy Biotech Company called, Tactiva Therapeutics in front of a packed house inside Roswell’s Research Center. Tactiva will develop the latest science to lead even more effective approaches at fighting and treating ...
-
NIH/NCI Small Business Innovation Research Grant, Awarded Fall 2019
Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...
By Nodexus Inc.
-
Symple Surgical, Inc. Retains Objective Capital Partners to Explore Strategic and Financial Partnerships
San Diego, CA and Flagstaff, AZ, April 12, 2018 — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital ...
-
Biosceptre secures £7m. to boost novel CAR T therapy
The funding, drawn from Norcliffe Capital in Europe and Jungle Capital in Australia, will help Biosceptre push it’s unique lead program towards clinical trials. “We are really pleased by this fund raise as it reaffirms confidence in our ground-breaking nfP2X7-targeted therapies, and the drastic difference they could make to the lives of thousands of cancer patients, ...
-
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers, and Stichting Oncode Institute (Oncode Institute), Utrecht, a major independent cancer research center, has led to an initial joint patent application covering LB-100 combination therapy ...
-
Matthew Gdovin, Ph.D. to Present at the 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology Satellite Session
Matthew Gdovin, Ph.D., University of Texas – San Antonio Professor and Chief Science Officer of Vitanova Biomedical, the San Antonio, Texas-based biotech company dedicated to delivering transformative cancer therapy utilizing their patented Light-Activated Intracellular Acidosis (LAIA) platform technology, will present at the 2nd International Prostate Cancer Symposium and Inaugural World ...
-
Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase I clinical trial of the Company’s next generation targeted inhibitor RGT-419B for the treatment of breast cancer. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase ...
-
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM). Novocure’s TTFields are electric fields that disrupt cancer cell ...
-
JCRI Discovers the Mechanism using Canady Helios Cold Plasma to Induce Cell Death in Breast Cancer
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), announced today that they have discovered the mechanism using Canady Helios™ Cold Plasma (CHCP) to induce cell death in breast cancer. Recently accepted for publication in the International Journal of Molecular Sciences, the article ...
-
Radiotherapy That Could Halve Prostate Cancer Treatment Time Recommended For Use in Wales
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...
By MediWales
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you